596 related articles for article (PubMed ID: 23370902)
1. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
Diabetic Retinopathy Clinical Research Network*
JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
[TBL] [Abstract][Full Text] [Related]
2. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Antoszyk AN; Glassman AR; Beaulieu WT; Jampol LM; Jhaveri CD; Punjabi OS; Salehi-Had H; Wells JA; Maguire MG; Stockdale CR; Martin DF; Sun JK;
JAMA; 2020 Dec; 324(23):2383-2395. PubMed ID: 33320223
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.
Yang CS; Hung KC; Huang YM; Hsu WM
J Ocul Pharmacol Ther; 2013; 29(6):550-5. PubMed ID: 23495932
[TBL] [Abstract][Full Text] [Related]
4. Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Beaulieu WT; Maguire MG; Antoszyk AN; Chow CC; Elman MJ; Jampol LM; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2021 Jul; 139(7):725-733. PubMed ID: 33956075
[TBL] [Abstract][Full Text] [Related]
5. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG;
JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371
[TBL] [Abstract][Full Text] [Related]
6. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
[TBL] [Abstract][Full Text] [Related]
7. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.
Sinawat S; Rattanapakorn T; Sanguansak T; Yospaiboon Y; Sinawat S
Eye (Lond); 2013 Dec; 27(12):1391-6. PubMed ID: 24037235
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.
Abd Elhamid AH; Mohamed AAEA; Khattab AM
BMC Ophthalmol; 2020 Apr; 20(1):130. PubMed ID: 32252674
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage.
Li S; Yang Y; Zou J; Zeng J; Ding C
BMC Ophthalmol; 2022 Feb; 22(1):63. PubMed ID: 35139812
[TBL] [Abstract][Full Text] [Related]
12. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy.
Bhavsar AR; Torres K; Glassman AR; Jampol LM; Kinyoun JL;
JAMA Ophthalmol; 2014 Jul; 132(7):889-90. PubMed ID: 25010170
[No Abstract] [Full Text] [Related]
14. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
15. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
Smith JM; Steel DH
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab versus vitrectomy for recurrent vitreous haemorrhage after pars plana vitrectomy for proliferative diabetic retinopathy: a prospective study.
Chatziralli I; Dimitriou E; Theodossiadis G; Bourouki E; Bagli E; Kitsos G; Theodossiadis P
Int Ophthalmol; 2020 Apr; 40(4):841-847. PubMed ID: 31788713
[TBL] [Abstract][Full Text] [Related]
19. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: a randomised, double-masked, placebo-controlled feasibility study.
Petrarca R; Soare C; Wong R; Desai R; Neffendorf J; Simpson A; Jackson TL
Acta Ophthalmol; 2020 Dec; 98(8):e960-e967. PubMed ID: 31674134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]